#1372

Improved CSPCa Detection Rate by MRI-TRUS Fusion Biopsy Compared to Conventional Biopsy: A Large Single-Center Experience

S. Niimura¹, N. Ohashi², Y. Kuroki², T. Niimura¹

¹Niimura Hospital, Department of Urology, Kagoshima, Japan
²Niimura Hospital, Department of Diagnostic Radiology, Kagoshima, Japan

Introduction:

The clinical significance of pre-biopsy MRI and PI-RADS v2 in detecting clinically significant prostate cancer (CSPCa) in patients with elevated PSA is widely recognized. Our institution has been performing MRI-TRUS fusion prostate biopsy since April 2017 and has accumulated experience with over 1800 cases by February 2024. This study aims to evaluate the CSPCa detection rate of MRI-TRUS fusion biopsy compared to our historical conventional biopsy method.

Material and methods:

We retrospectively analyzed 268 MRI-TRUS fusion biopsies (August 2021 - July 2022). The Gleason Grade Group (GG) 2-5 cancer detection rate (targeted + systematic) was assessed and compared to 485 conventional 12-core biopsies performed throughout the year 2015 (no prior MRI). Statistical analysis was performed using EZR (a graphical user interface for R), with p < 0.05 considered significant. The CSPCa (GG ≥ 2) detection rates of the two methods were statistically compared.

Results:

The overall detection rate of GG 2-5 cancer in the MRI-TRUS fusion biopsy group (n=268) was 82.5% (221/268). In the conventional biopsy group (n=485), the detection rate of GG 2-5 cancer was 34.6% (168/485). The MRI-TRUS fusion biopsy demonstrated a significantly higher CSPCa detection rate compared to the conventional method (p<0.001).